Get the Stockscreener App
64.65
1.49%
0.95
Pre-market:
64.67
0.02
+0.03%
Overview
News
Price History
Option Chain
Financials
Why BMY Down?
Discussions
Forecast
Stock Split
Dividend History
Bristol Myers Squibb Co stock is traded at $64.65, with a volume of 10.52M.
It is up +1.49% in the last 24 hours and up +8.95% over the past month.
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
See More
Previous Close:
$63.70
Open:
$64.05
24h Volume:
10.52M
Relative Volume:
0.88
Market Cap:
$132.06B
Revenue:
$48.48B
Net Income/Loss:
$7.27B
P/E Ratio:
18.15
EPS:
3.5626
Net Cash Flow:
$11.91B
1W Performance:
+0.78%
1M Performance:
+8.95%
6M Performance:
+6.44%
1Y Performance:
+35.11%
1-Day Range:
$63.91
$65.02
1-Week Range:
$63.00
$65.25
52-Week Range:
$42.52
$68.10
Bristol Myers Squibb Co Stock (BMY) Company Profile
Name
Bristol Myers Squibb Co
Sector
Industry
Phone
(609) 252-4621
Address
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Compare BMY vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
64.65 | 130.12B | 48.48B | 7.27B | 11.91B | 3.5626 |
LLY
Lilly Eli Co
|
1,209.00 | 1.09T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
262.08 | 628.65B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
250.82 | 439.59B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
135.55 | 327.94B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
151.72 | 289.52B | 54.66B | 13.58B | 16.05B | 7.0171 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-25-26 | Initiated | RBC Capital Mkts | Sector Perform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Upgrade | UBS | Neutral → Buy |
| Dec-15-25 | Upgrade | BofA Securities | Neutral → Buy |
| Dec-12-25 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Perform |
| Aug-05-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Apr-22-25 | Initiated | Piper Sandler | Overweight |
| Dec-16-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Nov-12-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-25-24 | Downgrade | Citigroup | Buy → Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jul-29-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-11-24 | Downgrade | Societe Generale | Buy → Hold |
| Feb-06-24 | Downgrade | Redburn Atlantic | Buy → Neutral |
| Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-15-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Oct-27-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Oct-27-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Oct-27-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jul-10-23 | Initiated | SVB Securities | Market Perform |
| Jun-28-23 | Initiated | Daiwa Securities | Outperform |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Jan-17-23 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-18-22 | Initiated | Credit Suisse | Neutral |
| Oct-10-22 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-14-22 | Downgrade | Berenberg | Buy → Hold |
| Jun-03-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Underweight |
| Dec-17-21 | Initiated | Goldman | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Nov-01-21 | Downgrade | Argus | Buy → Hold |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-30-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-13-21 | Upgrade | Truist | Hold → Buy |
| Nov-16-20 | Upgrade | Societe Generale | Hold → Buy |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Nov-06-20 | Downgrade | Gabelli & Co | Buy → Hold |
| Oct-19-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Jul-28-20 | Initiated | Raymond James | Outperform |
| Apr-02-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-06-20 | Resumed | Citigroup | Buy |
| Dec-13-19 | Upgrade | Argus | Hold → Buy |
| Nov-22-19 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Aug-14-19 | Upgrade | Atlantic Equities | Neutral → Overweight |
| May-28-19 | Initiated | Goldman | Buy |
| May-20-19 | Downgrade | Argus | Buy → Hold |
| May-03-19 | Upgrade | Barclays | Equal Weight → Overweight |
| May-03-19 | Resumed | JP Morgan | Overweight |
| Jan-15-19 | Upgrade | Societe Generale | Sell → Buy |
| Oct-22-18 | Downgrade | Citigroup | Buy → Neutral |
View All
Bristol Myers Squibb Co Stock (BMY) Latest News
Bristol Myers Squibb wins FDA accelerated approval for ZENBEXUS (iberdomide), its first CELMoD, in multiple myeloma - Dealroom
Is the Reported $400 Billion AstraZeneca-Bristol Myers Squibb Megamerger a Slam Dunk -- or a Disaster Waiting to Happen? - AOL.com
Bristol-Myers Can't Duck UMB Suit Targeting Drug Approvals - Law360
FDA approves Bristol Myers Squibb’s Zenbexus for multiple myeloma - Investing.com
US FDA approves Bristol Myers' blood cancer treatment - Reuters
FDA approves Bristol Myers Squibb’s Zenbexus for multiple myeloma By Investing.com - Investing.com UK
U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse - 巴士的報
ZENBEXUS becomes first FDA-approved CELMoD for myeloma - Stock Titan
Bristol-Myers Squibb Sued Over Heart Disease Treatment Patent - Bloomberg Law News
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - MarketWatch
Lawsuit against Bristol Myers over delayed cancer drug is revived - Reuters
Bristol-Myers Must Resume Court Fight on Drug Approval Diligence - Bloomberg Law News
Lawsuit against Bristol Myers over delayed cancer drug is revived By Reuters - Investing.com
Cytokinetics files lawsuit seeking patent judgment against Bristol-Myers Squibb - Investing.com
Atrium Therapeutics receives $15m milestone from Bristol Myers Squibb - Investing.com
Atrium Therapeutics receives $15m milestone from Bristol Myers Squibb By Investing.com - Investing.com UK
IMS Strategic Income Fund's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Vinod Khosla Says AI Is Creating a ‘Hyperabundance’ of New Drugs, but Testing Is Still ‘18th-Century’ - Benzinga
Bristol Myers Squibb stock holds near recent highs as AI drug discovery pact and Houston build-out r - AD HOC NEWS
Pharmacy giant Bristol Myers Squibb to build $2.3B Houston factory - ABC13 Houston
Is BMY's Growth Portfolio Strong Enough to Offset Legacy Drug Declines? - TradingView
Why Bristol Myers Squibb (BMY) Is Back In The Spotlight - simplywall.st
AstraZeneca focuses on future as BMS merger talk dismissed - Business Weekly
Handelsbanken Fonder AB Sells 446,938 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Assenagon Asset Management S.A. Boosts Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
How AstraZeneca’s $400bn deal unravelled - Financial Times
Bristol-Myers Squibb Co (BMY) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Bristol Myers Squibb to build $2.3B advanced manufacturing plant in Houston, creating 500 jobs - Waco Tribune-Herald
Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors - MarketWatch
Bristol-Myers Squibb Co (BMY) Stock News Today - TradingKey
BMS banks on Texas for $2.3bn multi-modal manufacturing facility - Pharmaceutical Technology
AstraZeneca's Failed $400 Billion Merger Talks with Bristol Myers Squibb - GuruFocus
Unique Wealth Strategies, LLC's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
News | Bristol Myers Squibb plans $2.3 billion Houston campus - CoStar
Bristol Myers Commits $2.3 Billion to Flexible Houston Drug Campus - TechStock²
Bristol Myers Squibb Unveils $2.3B Houston Life Science Project - CommercialSearch
Pharmaceutical giant to build $2.3B plant, create 500 jobs in Texas - USA Today
Bristol Myers Squibb picks Houston for $2.3B drug manufacturing campus - cw39.com
Bristol Myers Squibb to build $2.3B Houston pharma manufacturing campus - InnovationMap
Bristol Myers Squibb to Build $2.3 Billion Multi-Modal Manufacturing Campus in Houston - BioPharm International
BMY Rallies 16.2% in Three Months: Buy, Sell or Hold the Stock? - TradingView
New Bristol Myers Squibb facility coming to Generation Park - FOX 26 Houston
Pharma giant bets $2.3B on massive new Houston campus - Chron
Bristol Myers to build $2.3 billion manufacturing site in Houston - reuters.com
Bristol Myers Squibb to build $2.3B manufacturing campus in Houston - Investing.com
Bristol Myers to build $2.3 billion manufacturing site in Houston By Reuters - Investing.com
Bristol Myers Squibb to build $2.3 billion Texas facility - Investing.com
Bristol Myers Squibb commits to Houston with $2.3 billion manufacturing site - The Business Journals
Bristol Myers Squibb Plans $2.3 Billion Houston Manufacturing Campus - citybiz
$Bristol-Myers Squibb (BMY.US)$ - Moomoo
Bristol Myers Squibb's Planned Houston Campus to Create Nearly 500 Jobs - Stock Titan
Bristol Myers Squibb Co Stock (BMY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.86%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):